| Michael Loosemore, MD | |
|
3455 Main St Ste 5, New England Dermatology & Laser Center, Springfield, MA 01107-1147 | |
| (413) 733-9600 | |
| (413) 732-6534 |
| Full Name | Michael Loosemore |
|---|---|
| Gender | Male |
| Speciality | Micrographic Dermatologic Surgery (mds) |
| Experience | 17 Years |
| Location | 3455 Main St Ste 5, Springfield, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063619146 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| New England Dermatology Pc | 9436113677 | 18 |
News Archive
Mercator Therapeutics, the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs, today announced the signing of a license agreement with The University of Texas MD Anderson Cancer Center and the closing of a $2.0 million seed round.
Bruker Corporation, the leader in analytical magnetic resonance instrumentation, today announces a major order from the National Institute of Standards and Technology (NIST) for its ultra-high field AVANCE™ III 900 US2 NMR spectrometer.
A short time ago, Swedish scientists published a paper suggesting the existence of a genetic disposition to respond to placebo, thus giving rise to debate in the media about a possible "placebo gene." In the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2009; 106[46]: 751-5), Matthias Breidert and Karl Hofbauer summarize the most recent data about placebos.
People who swim, bathe or take part in water sports in the sea are substantially more likely to experience stomach bugs, earaches and other types of illness than those who do not.
› Verified 4 days ago
| Entity Name | New England Dermatology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356348098 PECOS PAC ID: 9436113677 Enrollment ID: O20041117000172 |
News Archive
Mercator Therapeutics, the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs, today announced the signing of a license agreement with The University of Texas MD Anderson Cancer Center and the closing of a $2.0 million seed round.
Bruker Corporation, the leader in analytical magnetic resonance instrumentation, today announces a major order from the National Institute of Standards and Technology (NIST) for its ultra-high field AVANCE™ III 900 US2 NMR spectrometer.
A short time ago, Swedish scientists published a paper suggesting the existence of a genetic disposition to respond to placebo, thus giving rise to debate in the media about a possible "placebo gene." In the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2009; 106[46]: 751-5), Matthias Breidert and Karl Hofbauer summarize the most recent data about placebos.
People who swim, bathe or take part in water sports in the sea are substantially more likely to experience stomach bugs, earaches and other types of illness than those who do not.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Loosemore, MD 3455 Main St Ste 5, New England Dermatology & Laser Center, Springfield, MA 01107-1147 Ph: (413) 733-9600 | Michael Loosemore, MD 3455 Main St Ste 5, New England Dermatology & Laser Center, Springfield, MA 01107-1147 Ph: (413) 733-9600 |
News Archive
Mercator Therapeutics, the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs, today announced the signing of a license agreement with The University of Texas MD Anderson Cancer Center and the closing of a $2.0 million seed round.
Bruker Corporation, the leader in analytical magnetic resonance instrumentation, today announces a major order from the National Institute of Standards and Technology (NIST) for its ultra-high field AVANCE™ III 900 US2 NMR spectrometer.
A short time ago, Swedish scientists published a paper suggesting the existence of a genetic disposition to respond to placebo, thus giving rise to debate in the media about a possible "placebo gene." In the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2009; 106[46]: 751-5), Matthias Breidert and Karl Hofbauer summarize the most recent data about placebos.
People who swim, bathe or take part in water sports in the sea are substantially more likely to experience stomach bugs, earaches and other types of illness than those who do not.
› Verified 4 days ago
Nadine P Wenner, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 3455 Main St, Ste 5, Springfield, MA 01107 Phone: 413-733-9600 Fax: 413-732-6534 | |
Sheila Greenlaw, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3455 Main St Ste 5, New England Dermatology & Laser Center, Springfield, MA 01107 Phone: 413-733-9600 Fax: 413-732-6534 | |
Dr. Michael D Horwich, MD, PHD Dermatology Medicare: Medicare Enrolled Practice Location: 3455 Main St Ste 5, New England Dermatology & Laser Center, Springfield, MA 01107 Phone: 413-733-9600 Fax: 413-732-6534 | |
David Wartman, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3455 Main St, Ste. # 5, Springfield, MA 01107 Phone: 413-733-9600 Fax: 413-732-6534 | |
Mark A Blumberg, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3455 Main St, Suite 5, Springfield, MA 01107 Phone: 413-733-9600 Fax: 413-732-6534 | |
Dr. Peter T Demos, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 125 Liberty St, Ste 403, Springfield, MA 01103 Phone: 413-739-6611 |